Low dose steroids

Small molecule

IImperial College London

Low dose steroids is one of 45 small molecule programs targeting Pneumonia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

Antiphospholipid SyndromeActive, not recruiting

PneumoniaPhase 2/Phase 3

Active, not recruiting

Antiphospholipid SyndromePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Primaxin

Pfizer

Preclinical

2 2

Jakafi

Incyte

Preclinical

1 3

Retrovir

BBp Consulting, Inc

Preclinical

2 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 5

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 6

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 7

Prograf

VVeloxis Pharmaceuticals

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Pepcid

KKenvue Brands

Preclinical

1 10

Aciphex

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2035

Phase 2/3Not yet recruiting

Pneumonia

NCT07152587

Clinical

Trials by Indication[1]

Pneumonia1 trial

Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

Not yet recruiting·QQingyuan Zhan·Phase 2/3·NCT07152587·1,500 enrolled

Antiphospholipid Syndrome1 trial

Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss

Withdrawn·IImperial College London·Phase 1/2·NCT00180778

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Low dose steroids. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low dose steroids compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low dose steroids. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Imperial College London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IImperial College London

Low dose steroids

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2035

Trials by Indication[1]

Pneumonia1 trial

Antiphospholipid Syndrome1 trial

References

Drug Info

Quick Facts

Related News